HiRO employed a proactive approach to achieve rapid start-up for a Phase 1 dermatology study. Our dedicated rapid start-up team, with over 20 years of experience, focused on swift ethics and regulatory approvals and concurrent site activation. We achieved full regulatory approval just 40 days from protocol receipt and screened the first patient only 3 days after site activation. Learn more about our rapid start-up strategies here: https://lnkd.in/gzAfAdYN #ClinicalTrials #RapidStartup #HiROANZ #HealthcareInnovation
HiRO - Harvest Integrated Research Organization’s Post
More Relevant Posts
-
🔍Uncover the secrets behind our Phase 3 dermatology trial success! Our latest case study shows how effective RBQM can protect data quality and ensure trial triumph. Get the inside scoop on real-world risk management and see how you can elevate your clinical trials. Check it out: https://hubs.ly/Q02FTx_B0 #ClinicalTrials #RBQM #DataQuality
To view or add a comment, sign in
-
Earlier this month, Clario was at #ISPOR2024 in Atlanta and presented two scientific posters. For those of you who missed them, below are a few takeaways. Compliance and Design Features of Electronic Participant-Reported Dosing Diaries 1) More consistency is needed in the types of questions dosing diaries include and standardization of requirements to support data quality. 2) High compliance over time and across studies with dosing diaries supports the use of eDiaries as an indicator for drug adherence. Electronic Collection of PRO Measures in Dermatology Trials 1) ePROs are common in dermatology trials and are targeted as primary and key secondary endpoints in successful FDA approvals. 2) Clario has successfully supported electronic collection of PROs in dermatology trials for primary and key secondary endpoints. For any questions on how to optimize your dosing diary or dermatology trial using ePROs, please contact science@clario.com #sciencematters #ePRO #ediaries
To view or add a comment, sign in
-
🌟 Successful USFDA Inspection at Our Dermatology Site. We are delighted to share that our recent USFDA inspection at one of our dermatology sites concluded with no 483/inspectional observations. However, we'd like to highlight two crucial recommendations from the inspection team that we believe if shared will benefit all stakeholders in clinical research industry. Recommendation 1: Ensure that completed CRFs come with the audit trail. The CRO initially did not provide the audit trail information along with the CRFs. Although the request was promptly addressed during the inspection, it is strongly recommended that CROs consistently provide audit trail information and sites should ensure that they recieved the same during close out or post close out. Recommendation 2: Utilize data loggers for recording IP temperature instead of manual recording from thermohygrometers. The inspector emphasized that relying solely on a hygrometer for temperature recording, which provides minimum and maximum values in a 24-hour period, might not capture multiple excursions. We have accepted this recommendation and assured the inspector that we will convey the same to the sponsor from the next study onwards. These recommendations are not just regulatory requirements but steps toward enhancing transparency, accuracy, and reliability in our clinical research processes. We value continuous improvement and are committed to implementing best practices. We would like to thank the inspection team for their valuable feedback and insights. #clinicalresearch #FDAInspection #DermatologyResearch 🌐🔬#clinicaloperations
To view or add a comment, sign in
-
With ReferralMD, Dermatology practices can: ✔️optimize their referral process for enhanced quality referrals ✔️streamline patient intake ✔️ensure seamless communication with referring providers ReferralMD's platform allows referral staff to efficiently manage referrals, schedule appointments, and facilitate effective communication with providers and patients, resulting in a more streamlined and effective process. Learn more at https://bit.ly/3IMqSPP #dermpractices #referralmanagement
To view or add a comment, sign in
-
Pioneering Caesarean Closure with Autologous Amniotic Fluid | Founder of CeaLogic | FemTech Entrepreneur | Patented | Medical Device | Proud Father | Avid Skier |
💡𝗣𝘂𝗯𝗠𝗲𝗱 article for a mechanism, sensibly supporting the use of 𝐀𝐮𝐭𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐀𝐦𝐧𝐢𝐨𝐭𝐢𝐜 𝐅𝐥𝐮𝐢𝐝 (𝐀𝐀𝐅) at Caesarean, published in the Journal of Cosmetic Dermatology. If hAFsc's are available in AAF at delivery, then the following 𝐑𝐄𝐒𝐔𝐋𝐓 can be hypothesized.. "𝑶𝒖𝒓 𝒓𝒆𝒔𝒖𝒍𝒕𝒔 𝒅𝒆𝒎𝒐𝒏𝒔𝒕𝒓𝒂𝒕𝒆𝒅 𝒕𝒉𝒂𝒕 𝒉𝑨𝑭𝑺 𝒂𝒄𝒄𝒆𝒍𝒆𝒓𝒂𝒕𝒆𝒅 𝒘𝒐𝒖𝒏𝒅 𝒄𝒍𝒐𝒔𝒖𝒓𝒆. 𝒉𝑨𝑭𝑺 𝒂𝒍𝒍𝒆𝒗𝒊𝒂𝒕𝒆𝒅 𝒔𝒄𝒂𝒓 𝒇𝒐𝒓𝒎𝒂𝒕𝒊𝒐𝒏 𝒗𝒊𝒂 𝒑𝒓𝒐𝒎𝒐𝒕𝒊𝒏𝒈 𝑬𝑪𝑴 𝒓𝒆𝒎𝒐𝒅𝒆𝒍𝒊𝒏𝒈, 𝒖𝒑𝒓𝒆𝒈𝒖𝒍𝒂𝒕𝒊𝒏𝒈 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒂𝒓 𝒐𝒇 𝒊𝒎𝒎𝒖𝒏𝒆 𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒆, 𝒆𝒏𝒉𝒂𝒏𝒄𝒊𝒏𝒈 𝒂𝒏𝒕𝒊𝒇𝒊𝒃𝒓𝒐𝒕𝒊𝒄 𝒂𝒄𝒕𝒊𝒗𝒊𝒕𝒚, 𝒂𝒏𝒅 𝒅𝒆𝒄𝒓𝒆𝒂𝒔𝒊𝒏𝒈 𝒕𝒉𝒆 𝒔𝒆𝒄𝒓𝒆𝒕𝒊𝒐𝒏 𝒐𝒇 𝒊𝒏𝒇𝒍𝒂𝒎𝒎𝒂𝒕𝒊𝒐𝒏-𝒂𝒔𝒔𝒐𝒄𝒊𝒂𝒕𝒆𝒅 𝒄𝒚𝒕𝒐𝒌𝒊𝒏𝒆𝒔 𝒕𝒉𝒓𝒐𝒖𝒈𝒉 𝒆𝒙𝒐𝒔𝒐𝒎𝒂𝒍 𝒎𝒊𝑹𝑵𝑨-146𝒂-5𝒑 𝒗𝒊𝒂 𝒕𝒂𝒓𝒈𝒆𝒕𝒊𝒏𝒈 𝑪𝑿𝑪𝑹4." Supporting data- for Activating and applying Autologous Amniotic Fluid at Caesarean closure. Article References in the comments #innovation, #medicine, #doctor, #obgyn, #obstetrics, #medicaldevices, #caeserean, #amnioticfluid
To view or add a comment, sign in
-
🧠 Discover our Complimentary CME Offering: 'Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light' with 1.00 CME Credits! 🌟 Unlock essential knowledge about managing psoriasis in patients with skin of color. Gain insights from experts Mona Shahriari, MD, and Andrew F. Alexis, MD, MPH, as they delve into clinical updates, treatment nuances, and strategies for personalized care. Don't miss this opportunity to earn CME credits and enhance your dermatology practice! Click the link below to start this activity 👇 https://lnkd.in/gkwmwGBp
To view or add a comment, sign in
-
Insights into the Pharma Dermatology Market – MAT May 2024. We're excited to share our latest analysis of the Pharma Dermatology market. Know the top-performing molecules and regions driving significant growth in this sector. Highlights include: - Key molecules showing impressive market growth - Regions leading in dermatology sales performance - In-depth market trends and data-driven insights Swipe through the slides to gain a deeper understanding of the market dynamics and discover the factors influencing these trends. Read complete report for MAT May 24' in https://lnkd.in/duRnrJJh Data set: MAT May 2024. #Pharmarack #PharmaDermatology #PharmaInsights #DermatologyTrends #PharmaIndustry
To view or add a comment, sign in
-
Gave a talk at Northeast Dermatology Conference on “A practical approach to using JAK inhibitors in dermatology”. Thanks for the great turnout! - via #Whova event app My 3-step approach to discussing the “boxed warning” : 1) NORMALIZE the boxed warning: we have a lot of medications in dermatology, including OTC, that also contain a boxed warning, but we continue to use these medications with regularity because we understand the context behind them. 2) CONTEXTUALIZE the boxed warning: different drugs, different diseases, different demographics WITHOUT a placebo group. This last point is crucial as we can interpret the ORAL surveillance study in 3 ways: A) Risk: JAKi > no treatment > TNFi B) Risk: JAKi = no treatment > TNFi C) Risk: no treatment > JAKi > TNFi *Time will tell but we also have to acknowledge that not treating/undertreating a disease has negative downstream effects as well. 3) REFERENCE long-term extension (which admittedly have limitations) and real world studies to show the incidence rates in patients who have AD but are not treated with a JAK inhibitor vs those who are treated with a JAK inhibitor. Spoiler alert: not much of an appreciable difference.
To view or add a comment, sign in
-
Assessing the ChatGPT aptitude: A competent and effective Dermatology doctor? - Study examines the efficacy of ChatGPT 3.5 and 4.0 in diagnosing atopic dermatitis and autoimmune blistering skin diseases (AIBD). - Method involved evaluation of ChatGPT responses to 50 questionnaires by five dermatologists. - Results show both versions can provide satisfactory answers for basic inquiries about atopic dermatitis, but are inadequate for diagnosing AIBD. - ChatGPT-4.0 performed better than ChatGPT-3.5 but did not surpass senior medical professionals. - Conclusion highlights the need for further development for ChatGPT's utility in the medical field. DOI: 10.1016/j.heliyon.2024.e37220 Link: https://lnkd.in/eWqG4bad
To view or add a comment, sign in
5,078 followers
More from this author
-
Navigating Clinical Trials in the Philippines and Malaysia: Insights and Opportunities
HiRO - Harvest Integrated Research Organization 2w -
Maximizing Global Study Value: Clinical Trial Landscapes in Korea and Japan
HiRO - Harvest Integrated Research Organization 1mo -
Strategies for Enhancing the Diversity of Clinical Trial Populations
HiRO - Harvest Integrated Research Organization 2mo